
zzso is worldwide one of today's most important medical and public health zzso zzso zzso is a relatively new drug in the pharmacological treatment of obesity which partially blocks fat zzso The following article analyses the available evidence of zzso effectiveness in the treatment of obese zzso 

Three zzso controlled trials investigating the effect of zzso in the treatment of obesity were identified by systematic zzso zzso The internal and external zzso of these studies was assessed using systematic zzso 

All three studies consistently demonstrate a treatment benefit of zzso compared to zzso Patients treated with zzso lost an average of zzso zzso more than patients taking zzso while on a zzso zzso zzso control of cardiovascular risk factors improved independently of the observed weight zzso Up to zzso of all patients experienced gastrointestinal side effects which were generally well zzso The studies prove that treatment with zzso can result in a moderate weight zzso However, the results of the studies cannot be easily zzso to obese patients in a primary care setting, due to limitations concerning the zzso internal and external zzso 

Based on these studies zzso is an efficient pharmacological treatment for obesity in patients adhering to a zzso zzso Studies demonstrating zzso effectiveness in a primary care setting are so far zzso From a public health perspective there is a need for a zzso controlled trial showing not only zzso effectiveness on surrogate markers in a primary care setting but, ideally, a reduction in zzso mortality and zzso 

